Lifeward (LFWD) Q4 2025 Earnings Transcript
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 21 2026
0mins
Source: NASDAQ.COM
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LFWD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LFWD
Wall Street analysts forecast LFWD stock price to fall
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 7.950
Low
4.50
Averages
4.50
High
4.50
Current: 7.950
Low
4.50
Averages
4.50
High
4.50
About LFWD
Lifeward Ltd, formerly known as ReWalk Robotics Ltd, is a medical device company. The Company is engaged in designing, developing, and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk again. The Company offers an exoskeleton that uses its tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. Lifeward designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers multiple products: ReWalk Personal, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities and is custom-fitted for each user. Lifeward Rehabilitation products are for use by paraplegia patients in the clinical rehabilitation environment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lifeward (LFWD) Q4 2025 Earnings Transcript
See More
Lifeward Appoints New Chief Medical Officer
- Executive Appointment: Lifeward Ltd. announced the appointment of Keith Rose as Chief Medical Officer, who previously served as Vice President of Medical Affairs and Medical Director of Neurosciences, tasked with leading the company's global medical strategy, which is expected to drive further advancements in the medical technology sector.
- Extensive Experience: Keith Rose brings over 30 years of experience in rehabilitation medicine, neuroscience, and medical affairs, having held senior medical affairs and clinical leadership roles at Biocodex, Novocure, Ipsen Bioscience, Jazz Pharmaceuticals, and Indivior, which will provide Lifeward with valuable industry insights and expertise.
- Strategic Expansion: CEO Mark Grant stated that this appointment supports the company's efforts to expand its rehabilitation technology portfolio and advance newly acquired biomedical assets, demonstrating the company's strategic ambitions in the medical technology field.
- Market Reaction: Following the announcement, Lifeward's stock closed down 1.79% at $6.58 on Nasdaq, reflecting a cautious market sentiment regarding the company's future developments.
See More
Lifeward Ltd. Q1 2026 Earnings Call Insights
- Acquisition Milestone: Lifeward successfully completed the acquisition of Oratech in Q1 2026, strengthening its position as a diversified biomedical innovation company focused on neurorehabilitation, while maintaining minimal near-term operational burden.
- Financial Performance Review: Revenue for Q1 2026 was $3.9 million, down from $5 million in Q1 2025, primarily impacted by working capital constraints, although ReWalk personal exoskeleton sales increased by 11% year-over-year to $1.6 million.
- Liquidity Enhancement: Lifeward significantly improved its balance sheet with $10 million from convertible note financing, ending the quarter with $11.4 million in unrestricted cash and cash equivalents, a substantial increase from $2.2 million at the end of 2025.
- Cautious Future Outlook: Management expects overall revenue for 2026 to be similar to 2025 despite a weaker Q1, expressing optimism for sales growth in the coming months, particularly driven by a backlog of AlterG orders.
See More
Lifeward Reports Q1 Loss with Revenue Decline
- Earnings Loss: Lifeward reported a Q1 Non-GAAP EPS of -$3.13 with revenue of $3.92 million, reflecting a 22.1% year-over-year decline and missing expectations by $1.86 million, indicating significant competitive pressure on the company.
- Improved Cash Position: As of March 31, 2026, Lifeward had $11.4 million in unrestricted cash and cash equivalents, a substantial increase from $2.2 million as of December 31, 2025, demonstrating progress in financial management.
- Operational Efficiency Gains: Cash used in operating activities decreased to $3.7 million in Q1 2026 from $5.5 million in Q1 2025, primarily due to improved operational efficiencies and working capital management, highlighting effective cost control measures.
- Strategic Expansion Signals: Lifeward is signaling a strategic expansion into oral insulin and AI-powered rehabilitation through a partnership with Oramed, indicating a proactive approach to entering new markets and enhancing future growth potential.
See More
Lifeward Q1 Earnings Announcement Scheduled
- Earnings Release Date: Lifeward (LFWD) is set to announce its Q1 earnings on May 15th after market close, with a consensus EPS estimate of -$0.34, reflecting a 22.7% year-over-year improvement, indicating the company's efforts to enhance financial performance amid challenges.
- Revenue Expectations: The anticipated revenue for Q1 is $5.78 million, representing a 14.9% year-over-year increase, which, despite existing challenges, demonstrates some growth potential and reflects the company's adaptability in the market.
- Historical Performance: Over the past two years, Lifeward has only beaten EPS estimates 13% of the time and revenue estimates 25% of the time, indicating difficulties in meeting financial targets, which may impact investor confidence.
- Strategic Partnership: Lifeward's collaboration with Oramed signifies a strategic expansion into oral insulin and AI-powered rehabilitation, suggesting that despite current financial struggles, this initiative could lay the groundwork for future growth.
See More
Lifeward to Report Q1 2026 Financial Results on May 15
- Earnings Announcement: Lifeward will release its Q1 2026 financial results before U.S. markets open on May 15, reflecting the company's ongoing commitment to transparency and investor communication.
- Executive Conference Call: Following the earnings release, CEO Mark Grant and CFO Almog Adar will host a conference call at 8:30 a.m. EDT to provide in-depth analysis of the financial results and address investor inquiries.
- Product Portfolio Overview: Lifeward's portfolio includes market-leading neurorehabilitation technologies such as the ReWalk® Exoskeleton and AlterG® Anti-Gravity System, showcasing the company's strong position in biomedical innovation.
- Strategic Transformation: The company is evolving into a diversified biomedical firm, expanding into high-value therapeutic platforms, particularly its oral delivery system targeting the diabetes market, indicating a focus on future growth opportunities.
See More
Lifeward (LFWD) Q4 2025 Earnings Transcript
See More
Lifeward Appoints New Chief Medical Officer
- Executive Appointment: Lifeward Ltd. announced the appointment of Keith Rose as Chief Medical Officer, who previously served as Vice President of Medical Affairs and Medical Director of Neurosciences, tasked with leading the company's global medical strategy, which is expected to drive further advancements in the medical technology sector.
- Extensive Experience: Keith Rose brings over 30 years of experience in rehabilitation medicine, neuroscience, and medical affairs, having held senior medical affairs and clinical leadership roles at Biocodex, Novocure, Ipsen Bioscience, Jazz Pharmaceuticals, and Indivior, which will provide Lifeward with valuable industry insights and expertise.
- Strategic Expansion: CEO Mark Grant stated that this appointment supports the company's efforts to expand its rehabilitation technology portfolio and advance newly acquired biomedical assets, demonstrating the company's strategic ambitions in the medical technology field.
- Market Reaction: Following the announcement, Lifeward's stock closed down 1.79% at $6.58 on Nasdaq, reflecting a cautious market sentiment regarding the company's future developments.
See More
Lifeward Ltd. Q1 2026 Earnings Call Insights
- Acquisition Milestone: Lifeward successfully completed the acquisition of Oratech in Q1 2026, strengthening its position as a diversified biomedical innovation company focused on neurorehabilitation, while maintaining minimal near-term operational burden.
- Financial Performance Review: Revenue for Q1 2026 was $3.9 million, down from $5 million in Q1 2025, primarily impacted by working capital constraints, although ReWalk personal exoskeleton sales increased by 11% year-over-year to $1.6 million.
- Liquidity Enhancement: Lifeward significantly improved its balance sheet with $10 million from convertible note financing, ending the quarter with $11.4 million in unrestricted cash and cash equivalents, a substantial increase from $2.2 million at the end of 2025.
- Cautious Future Outlook: Management expects overall revenue for 2026 to be similar to 2025 despite a weaker Q1, expressing optimism for sales growth in the coming months, particularly driven by a backlog of AlterG orders.
See More
Lifeward Reports Q1 Loss with Revenue Decline
- Earnings Loss: Lifeward reported a Q1 Non-GAAP EPS of -$3.13 with revenue of $3.92 million, reflecting a 22.1% year-over-year decline and missing expectations by $1.86 million, indicating significant competitive pressure on the company.
- Improved Cash Position: As of March 31, 2026, Lifeward had $11.4 million in unrestricted cash and cash equivalents, a substantial increase from $2.2 million as of December 31, 2025, demonstrating progress in financial management.
- Operational Efficiency Gains: Cash used in operating activities decreased to $3.7 million in Q1 2026 from $5.5 million in Q1 2025, primarily due to improved operational efficiencies and working capital management, highlighting effective cost control measures.
- Strategic Expansion Signals: Lifeward is signaling a strategic expansion into oral insulin and AI-powered rehabilitation through a partnership with Oramed, indicating a proactive approach to entering new markets and enhancing future growth potential.
See More
Lifeward Q1 Earnings Announcement Scheduled
- Earnings Release Date: Lifeward (LFWD) is set to announce its Q1 earnings on May 15th after market close, with a consensus EPS estimate of -$0.34, reflecting a 22.7% year-over-year improvement, indicating the company's efforts to enhance financial performance amid challenges.
- Revenue Expectations: The anticipated revenue for Q1 is $5.78 million, representing a 14.9% year-over-year increase, which, despite existing challenges, demonstrates some growth potential and reflects the company's adaptability in the market.
- Historical Performance: Over the past two years, Lifeward has only beaten EPS estimates 13% of the time and revenue estimates 25% of the time, indicating difficulties in meeting financial targets, which may impact investor confidence.
- Strategic Partnership: Lifeward's collaboration with Oramed signifies a strategic expansion into oral insulin and AI-powered rehabilitation, suggesting that despite current financial struggles, this initiative could lay the groundwork for future growth.
See More
Lifeward to Report Q1 2026 Financial Results on May 15
- Earnings Announcement: Lifeward will release its Q1 2026 financial results before U.S. markets open on May 15, reflecting the company's ongoing commitment to transparency and investor communication.
- Executive Conference Call: Following the earnings release, CEO Mark Grant and CFO Almog Adar will host a conference call at 8:30 a.m. EDT to provide in-depth analysis of the financial results and address investor inquiries.
- Product Portfolio Overview: Lifeward's portfolio includes market-leading neurorehabilitation technologies such as the ReWalk® Exoskeleton and AlterG® Anti-Gravity System, showcasing the company's strong position in biomedical innovation.
- Strategic Transformation: The company is evolving into a diversified biomedical firm, expanding into high-value therapeutic platforms, particularly its oral delivery system targeting the diabetes market, indicating a focus on future growth opportunities.
See More
